Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Price Isn't Enough: Sandoz Hones Biosimilars Strategy With Lessons From Omnitrope

Executive Summary

As FDA fleshes out the beginnings of a biosimilar regulatory pathway in the U.S., Novartis AG's generics business Sandoz is starting to draw important lessons in how to effectively commercialize copy-cat biologics.

You may also be interested in...

Biosimilar But Different: Zarxio, Neupogen Diverge On Syringes, Vials

Differences in product presentation may not have much market impact now but could prove a regulatory challenge if Sandoz pursues an interchangeability determination down the line.

Biosimilar Pricing: Sandoz Vows Not To Make Omnitrope ‘Mistake’ With Filgrastim

Sandoz, Hospira execs say U.S. payers and consumers will ‘not be disappointed’ in cost savings from products approved under the 351(k) pathway, but warn that price alone may not tell whole story.

Biosimilar Insulin: Why Novo Knows No Fear

Even after the largest pharmaceutical company in the sector, Pfizer Inc., announced it was laying a stake in the biosimilar insulin market, Danish diabetes leader Novo Nordisk A/S – about one-fifth the size of Pfizer in sales terms, although its market cap is just under half of Pfizer's – didn't flinch.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts